XENON XE 133 (xenon xe-133) by Lantheus Medical Imaging is radiopharmaceutical activity [moa]. First approved in 1974.
Drug data last refreshed 4h ago · AI intelligence enriched 1mo ago
Xenon XE-133 is an inhalation diagnostic radiopharmaceutical gas approved in 1974 for pulmonary imaging and ventilation assessment. It enables clinicians to visualize lung function and detect regional ventilation defects in patients with suspected pulmonary disease. The agent works through inhalation absorption and regional distribution in the lungs, allowing nuclear medicine imaging.
This legacy diagnostic product faces moderate competitive pressure (30%) with limited growth potential, suggesting small-sized brand teams focused on maintenance rather than expansion.
Radiopharmaceutical Activity
Inhalation Diagnostic Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Xenon XE-133 offers limited career advancement due to zero linked job openings and the product's mature, LOE-approaching lifecycle stage. Roles are likely focused on compliance, manufacturing efficiency, and market maintenance rather than strategic growth or innovation.
Worked on XENON XE 133 at Lantheus Medical Imaging? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.